<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Lenalidomide; Thalidomide" /><meta name="IX" content="Lenalidomide; Thalidomide" /><title>Lenalidomide and thalidomide: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="200217.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="200217.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=200217.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4777.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="4789.htm">8.2.4 Other immunomodulating drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="207295.htm" title="Previous: HISTAMINE DIHYDROCHLORIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="200218.htm" title="Next: LENALIDOMIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a306005.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a399032.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Biologic Response Modifiers 92:20</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/21031-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Lenalidomide</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: L &gt; Interactions of Lenalidomide</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/13316-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Thalidomide</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: T &gt; Interactions of Thalidomide</p></div></li></ul><ul><li><h3>British National Formulary (5)</h3></li><li><a href="3925.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">5.1.10 Antileprotic drugs</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 5 Infections &gt; 5.1 Antibacterial drugs</p></div></li><li><a href="200218.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">LENALIDOMIDE</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Lenalidomide and thalidomide</p></div></li><li><a href="200219.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Revlimid®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Lenalidomide and thalidomide &gt; LENALIDOMIDE</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22lenalidomide%22%22thalidomide%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/c-d1e1106708.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/21031-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/24935-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pomalidomide</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/13316-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/05436.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; L &gt; LE</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09255.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; T &gt; TH</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E6E3E0R0D1488.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Lenalidomide</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; L</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E14E3E0R0D1488.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Thalidomide</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; T</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_200217">Lenalidomide and thalidomide</h1><?highlighter on?><div id="pC" class="jN"><div><div id="_200384"><p><b>Lenalidomide</b> is an immunomodulating drug with antineoplastic, anti-angiogenic,
and pro-erythropoietic properties. It is licensed, in combination
with dexamethasone, for the treatment of multiple myeloma in patients
who have received at least one previous therapy.</p><p>The most serious side-effects of lenalidomide are venous thromboembolism
and severe neutropenia. Lenalidomide is structurally related to thalidomide
and there is a risk of teratogenesis.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (April 2010) that lenalidomide, in combination with
dexamethasone, is accepted for restricted use within NHS Scotland
for patients with multiple myeloma who have received at least two
prior therapies.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Lenalidomide for the treatment of multiple myeloma
(June 2009)</h3><p>Lenalidomide in combination with dexamethasone is an option
for the treatment of multiple myeloma in patients who have received
two or more prior therapies. The drug cost of lenalidomide will be
met by the manufacturer for patients who remain on treatment for more
than 26 cycles.</p></div></div><p><b>Thalidomide</b> is used in combination with melphalan
and prednisolone as first-line treatment for untreated multiple myeloma,
in patients aged 65 years and over, or for those not eligible for
high-dose chemotherapy (for example, patients with significant co-morbidity
such as cardiac risk factors). It has immunomodulatory and anti-inflammatory
activity. Thalidomide can cause drowsiness, constipation, and on prolonged
use peripheral neuropathy.</p><div id="_218382"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Bortezomib and thalidomide for the first-line treatment
of multiple myeloma (July 2011)</h3><p>Thalidomide in combination with an alkylating drug and a corticosteroid
is recommended as an option for the first-line treatment of multiple
myeloma in people for whom high-dose chemotherapy with stem cell transplantation
is considered inappropriate.</p><p>For bortezomib see <a title="BNF:target-block: NICE bortezomib and thalidomide 1" href="128312.htm#_218151">under Bortezomib</a></p></div></div><div id="_201713"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">For women of child-bearing
potential, pregnancy must be excluded before starting treatment (perform
pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least
1 month before, during, and for at least 1 month after treatment (oral
combined hormonal contraceptives and copper-releasing intrauterine
devices not recommended) and men should
use condoms during treatment and for at least 1 week after stopping
if their partner is pregnant or is of child-bearing potential and
not using effective contraception. Women
must comply with a pregnancy prevention programme.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_200218"><a href="200218.htm" title="LENALIDOMIDE">LENALIDOMIDE</a></li><li id="_201478"><a href="201478.htm" title="THALIDOMIDE">THALIDOMIDE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="207295.htm">Previous: HISTAMINE DIHYDROCHLORIDE</a> | <a class="top" href="200217.htm#">Top</a> | <a accesskey="]" href="200218.htm">Next: LENALIDOMIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>